Will Novartis' Copycat Zarxio Approval Be a Game Changer for U.S. Biologic Drug Market?

SUGAR LAND--March 11, 2015--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--The U.S. biologics playing field is taking on a whole new aspect with the approval of the drug Zarxio, a similar version of Amgen's (NASDAQ:AMGN) (Thousand Oaks, California) cancer drug Neupogen (filgrastam). Novartis AG (NYSE:NVS) (Basel, Switzerland) is now free to market Zarxio through Sandoz, its generic division in the U.S. The key word is "similar," as in "biosimliar," the industry's term for generic or copycat biologic drugs.

Within this article: Details on the difference between biosimilars and other generic drugs, with a look at their standing in the Pharmaceutical & Biotech Industry.